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Glossary of Abbrevations 35 
- VKA: vitamin K antagonists 36 
- OAC: oral anticoagulation 37 
- INR: International Normalized Ratio 38 
- TTR: Time in Therapeutic Range 39 
- ICD: International Classification of Diseases 40 
- NCSP: NOMESCO Classification of Surgical Procedures  41 
- ATC: Anatomical Therapeutic Chemical classification 42 
- MAV: mechanical aortic valve 43 
- MMV: mechanical mitral valve  44 















Central Message 47 
We show that low versus high quality of vitamin K ant gonist therapy, defined as time in 48 
therapeutic range <70% versus >70%, is associated with a higher risk of thromboembolism but not 49 















Perspective Statement 52 
Oral anticoagulation with vitamin K antagonists (VKA) is recommended after mechanical heart 53 
valve replacement. However, data regarding the association between the quality of VKA treatment 54 
and the risk of complications are sparse. This manuscript contributes with important research 55 

















Objective: Oral anticoagulation with vitamin K antagonists (VKA) is recommended after 60 
mechanical heart valve replacement. However, data reg rding the association between the quality of 61 
VKA treatment and the risk of complications are spar e. 62 
Methods: Patients undergoing mechanical heart valve replacement (1997-2012) with available data 63 
on International Normalized Ratio (INR) values were id ntified in Danish registries. The quality of 64 
VKA treatment between discharge after valve replacement and 6 months post-discharge (index) was 65 
assessed as time in therapeutic range (TTR) >70% or <70% reflecting the percentage of time in 66 
therapeutic INR interval. Patients were followed from index until occurrence of an outcome of 67 
interest (i.e. thromboembolism and bleeding), death, or end of study (December 31, 2012), 68 
whichever came first. The risk of outcomes according to quality of VKA treatment was estimated 69 
with multivariable Cox regression. 70 
Results: In total, 659 patients undergoing mechanical heart v lve replacement were included in the 71 
study. Median number of INR measurements in the 6-month period after surgery was 13 (IQR 8-72 
19). Median TTR was 54.9% (IQR 39.0-72.9) and 29.1% of patients had a TTR≥70%. Median 73 
follow-up was 6.1 years. The risk of thromboembolism was significantly lower in the group with 74 
TTR≥70% compared with TTR<70% (Hazard ratio (HR) 0.44, 95% CI 0.22-0.85), while no 75 
significant difference concerning risk of bleeding among groups was found (HR 0.63, 95% CI 0.36-76 
1.08). 77 
Conclusion: In patients undergoing mechanical heart valve replacement, TTR<70% in the 6-month 78 
period after surgery was associated with an increased risk of thromboembolic events but not 79 
bleedings compared with TTR>70%. 80 
 81 
















More than 100 million people worldwide suffer from valve diseases and the prevalence is expected 85 
to increase concurrently with increasing life expectan y.1 Worldwide, approximately 300,000 valve 86 
replacements are carried out annually1 and oral anticoagulation (OAC) therapy in patients with 87 
mechanical prosthesis is crucial in order to reduce the risk of thromboembolic complications and 88 
mortality. This comes at a natural price of an increased bleeding risk; hence, tight control of OAC 89 
therapy is clinically important in finding the optimal balance between effectiveness and safety. 90 
Mechanical prostheses are recommended for patients younger than 65 years because of a long 91 
durability compared with bioprosthetic valves, yet they are associated with a higher risk of 92 
thromboembolic events and life-long OAC therapy with vitamin K antagonists (VKA) is 93 
recommended.2 VKA have a slow on- and offset, a narrow therapeutic window, and a variable dose-94 
response relationship and exhibit several drug-drug and drug-food interactions.1 Further, guidelines 95 
recommend a continuous patient control in order to closely monitor the quality of the VKA 96 
treatment as variability of International Normalized Ratio (INR) or by Time in Therapeutic Range 97 
(TTR).2,3 98 
Although the importance of a well-regulated VKA treatment in patients with atrial fibrillation is 99 
well established4,5,6,7, little work has been done to clarify the impact of TTR on the risk of 100 
complications in mechanical heart valve patients. Among AF patients, studies have shown an 101 
association between low quality of VKA treatment and the risk of outcomes, while studies on 102 
patients with mechanical heart valve patients have shown contradictory results.8,9,10,11 This 103 
nationwide carefully designed study sets out to examine the association between TTR and the risk 104 
















Data sources 108 
All residents in Denmark are assigned a unique and permanent civil registration number allowing 109 
accurate linkage of nationwide administrative registrie  at an individual level. The Danish National 110 
Patient Registry contains information on all hospital admissions, diagnoses (coded according to the 111 
International Classification of Diseases (ICD) eighth and tenth revision), and surgical procedures 112 
(coded according to the NOMESCO Classification of Surgical Procedures (NCSP)) since 1978. The 113 
Danish National Prescription Registry holds information on all claimed prescriptions since 1995 114 
(coded according to the Anatomical Therapeutic Chemical (ATC) classification) including date of 115 
drug dispensation, strength, and quantity. All pharmacies in Denmark are by legislation obliged to 116 
register all dispensed prescriptions in order to ensure complete and accurate registration.12 The 117 
Danish National Population Registry holds information on vital status and contains information on 118 
all deaths. 119 
Information on INR values was obtained through registries of laboratory databases from general 120 
practitioners and from hospitals in the bigger part of Denmark including Northern Jutland and 121 
Zealand from 1st of January 1997 to 31th of December 2012. 122 
 123 
Study population and TTR calculation 124 
The study population comprised patients who underwent isolated mechanical aortic valve (MAV) or 125 
mechanical mitral valve (MMV) replacement (NCSP codes: KFMD00 and KFKD, respectively) in 126 
the period 1st of January 1997 to 31th of December 2012. Patients were followed from index (6 127 
months post-surgery) until occurrence of an outcome (i.e. thromboembolism or bleeding), death, a 128 
maximum ten years of follow-up, or end of follow-up (December 31, 2012), whichever came first. 129 
Patients were excluded if they had undergone previous heart surgery, died before index, or 130 














MAVR and MMVR (n=21), these patients were excluded from the study. The quality of VKA 132 
treatment can be described by means of TTR reflecting the percentage of time the patient has been 133 
in therapeutic INR interval. Current guidelines recommend an INR of 2.0-3.0 or 2.5-3.5 for patients 134 
with MAV and MMV, respectively.2 TTR was calculated in the period from baseline (date of 135 
discharge) to index. TTR was assessed by the Rosendaal method, calculated as the total time in 136 
therapeutic interval divided by total time of observation. This method assumes a linear correlation 137 
between INR measurements and requires at least three INR values6,13,14; hence, patients with less 138 
than three INR values before index were excluded (Figure 1). The patients excluded due to lack 139 
of/insufficient INR values were comparable to the included patients. In order to calculate an 140 
accurate TTR in the period from baseline to index, the TTR calculation was not started until the 141 
patient was above the lower limit of their target therapeutic INR range i.e. 2.0 and 2.5 for patients 142 
with MAV and MMV, respectively, thus the individual period of TTR calculation could be less than 143 
6 months. TTR calculation was stopped if more than 60 days passed between two successive 144 
measurements to ensure a precise analysis of the anico gulation; hence, patients with more than 60 145 
days between their two first INR measurements were excluded from the study (Figure 1). Thus, it is 146 
critical to have available and sufficient INR values in order to calculate TTR. In order to accurately 147 
access a reliable TTR, follow-up was initiated 6 months following discharge. According to current 148 
European guidelines2 TTR ≥70% is considered high quality and consequently TTR <70% is 149 
considered low quality; thus, the study population was stratified into two groups according to their 150 
TTR value.  151 
 152 
Covariates 153 
Comorbidities were defined as at least one hospitalization any time prior to baseline (ICD-codes in 154 














drug prescriptions as done previously.15 Concomitant pharmacotherapy was defined by at leasone 156 
filled prescription within six months prior to baselin . 157 
 158 
Outcomes 159 
Outcomes included thromboembolism, bleeding events, a d all-cause mortality. Thromboembolism 160 
was defined as a composite of valve thrombosis, stroke, AMI, or arterial embolism (ICD-codes in 161 
Supplementary Table 1). Bleeding was defined as a major bleeding event requiring hospital 162 
admission (ICD-codes in Supplementary Table 1). Thromboembolism have previously been 163 
validated with high positive predictive values.16–18  164 
 165 
Statistical analysis 166 
Differences in baseline characteristics according to TTR were tested using the chi-square test for 167 
categorical variables and the Mann-Whitney test for c ntinuous variables. Multivariable logistic 168 
regression was applied to identify baseline characte istics associated with TTR >70%. The 169 
cumulative incidences of thromboembolism and bleeding were estimated using the Aalen-Johansen 170 
estimator incorporating competing risk of death, whereas the cumulative incidence of all-cause 171 
mortality was estimated using the Kaplan-Meier estima or. Differences between groups were 172 
assessed using Gray’s test and the log-rank test, rpectively. In order to calculate hazard ratios 173 
(HR) for thromboembolism, bleeding, and all-cause mortality, we used multivariable cause-specific 174 
Cox regression models adjusted for sex, age, valve typ , comorbidities listed in Table 1, and 175 
concomitant pharmacotherapy listed in Table 1. The proportional hazards assumption was tested 176 
and found valid. Relevant interactions were tested an  found insignificant, unless otherwise stated. 177 
All statistical analyses were performed with SAS stati ical software (SAS 9.4, SAS Institute, Cary, 178 















Sensitivity analyses 181 
To test the robustness of our findings, we assessed quality of VKA treatment by INR variability. 182 
INR variability was assessed as variance growth rate described and defined by Finn et al.19 The 183 
variance growth rate reflects the degree to which a patient’s INR deviates from his or her previous 184 
INR not taking the intensity of anticoagulation into account. Thus, the variability refers to the 185 
standard deviation of a linear curve of interpolated INR measurements. A mean of INR variability 186 
of 0.75 was chosen since the median (Supplementary T ble 4) was shown to be 0.75. Thus, INR 187 
variability >0.75 was considered as high deviation, whereas INR variability <0.75 was considered 188 
as low deviation. Furthermore, a multivariable Cox regression with TTR as a time-dependent 189 
variable was performed adjusted for the aforementioned covariates. TTR was calculated 190 
continuously from three sequential INR values in the period from baseline to occurrence of an 191 
outcome (i.e. thromboembolism or bleeding), death,  maximum ten years of follow-up, or end of 192 
follow-up (December 31, 2012), whichever came first. The study population in the time dependent 193 
analysis consisted of 670 patients, since no patients with outcomes in the follow-up period were 194 
excluded. Moreover, propensity score stratification analyses were performed as a balancing method. 195 
Hazard ratios were generated using Cox proportional hazards regression stratified in three groups 196 
according to the propensity to achieve a TTR>70%. Propensity scores were calculated using a 197 
multi-variable logistic regression with the dependet outcome as achieving a TTR>70%. The 198 
propensity scores were generated from the covariates pr sented in Figure 2. The C index of the 199 
propensity model was 0.6 indicating relatively good discrimination. Stratification on propensity 200 
scores ensured comparison only within strata of propensity scores. 201 
 202 














The study was approved by the Danish Data protection Agency (reference no: 2007-58-0015/GEH-204 
2014-012, I-suite no: 02720). Ethical approval is not required for retrospective register-based 205 




A total of 659 patients undergoing mechanical heart v lve (MHV) replacement were included in the 210 
study; of these, the majority (80.0%) underwent mechanical aortic valve replacement (Figure 1). 211 
The median age of the study population was 58.0 years (interquartile range (IQR) 50-64) and 70.1% 212 
were men. The median amount of INR measurements in the 6-month period after surgery was 13 213 
(IQR 8-19). Baseline characteristics for the overall study population and according to TTR are 214 
shown in Table 1.  215 
 216 
Time in therapeutic range 217 
Overall, 29.1% of the study population had a TTR ≥70%. Median TTR was 54.9 (IQR 39.0-73.1) 218 
and was higher among patients with MAV than patients with MMV (58.9% and 37.0%, 219 
respectively) (Table 2). The median of the average INR value was 2.6 among patients with MMV 220 
(therapeutic range 2.5-3.5) and 2.4 among patients with MAV (therapeutic range 2.0-3.0). Results 221 
from the multivariable logistic regression on factors associated with a TTR ≥70% are shown in 222 
Figure 2. In general, baseline characteristics in the two groups were similar, though TTR <70% was 223 
associated with mechanical mitral valve replacement (Odds Ratio 0.17, 95% confidence interval 224 
(95% CI) 0.17-0.53, P<0.001). Among the excluded 21 patients who underwent both MAVR and 225 
















During a median follow-up of 6.1 years, 79 patients experienced a thromboembolic event (AMI 229 
n=20, stroke n=57, arterial embolism n=3, valve thrombosis n=2). In total, 66 of the patients with a 230 
TTR <70% and 13 of the patients with a TTR ≥70% had a thromboembolic event. A significant 231 
difference was found when looking at the unadjusted cumulative incidence curve (P=0.011) (Figure 232 
3). Also, in the multivariable model (Table 3) the risk of thromboembolism was significantly lower 233 
in the group with TTR ≥70% compared with TTR <70% (Hazard ratio (HR) 0.44, 95% CI 0.22-234 
0.85, P=0.015).  235 
     During the follow-up period, 94 patients experienced a bleeding event. When stratified 236 
according to TTR, 69 of the patients with a TTR <70% and 25 of the patients with a TTR ≥70% 237 
experienced a bleeding event. In the cumulative incidence curve (Figure 4) and in the multivariable 238 
analysis (Table 3), no significant difference was found concerning risk of bleedings among groups 239 
(TTR>70% vs. TTR<70%) (P=0.60 and HR 0.63, 95% CI 0.36-1.08, P=0.094, respectively).  240 
     Patients with a history of stroke, ischemic heart disease, atrial fibrillation, or hypertension were 241 
at risk of for thromboembolic events, whereas patients with prior bleeding event, a history of 242 
hypertension, or abnormal liver function were at risk of a new bleeding event. Supplementary Table 243 
2 and 3 summarize factors associated with thromboemlic events and bleedings, respectively. 244 
Among patients experiencing a first-time outcome (i. . thromboembolic event or bleeding), 3 and 9 245 
patients experienced a recurrent thromboembolic event or bleeding, respectively. 246 
     During the follow-up period, 95 patients died and the incidence of mortality was shown to be 247 
lower in the group with TTR ≥70% compared with the group with TTR <70% (n=21 and n=74, 248 
respectively). TTR >70% was shown to be associated with a similar risk of mortality compared 249 
with TTR <70% in the cumulative incidence curve (P=0.15) (Figure 5) and in the multivariable 250 
analysis (Table 3) (HR 0.84, 95% CI 0.50-1.42, P=0.52).  251 
 252 














A sensitivity analysis was performed using INR variability as an alternative way of describing the 254 
quality of anticoagulation treatment. Median INR variability was 0.75 (IQR 0.49-1.16). Overall, 255 
67.7% of the population group had INR variability <0.75; however, it concerned 55.2% of the 256 
MAV patients and 29.6% of the MMV patients (Supplementary Table 4). In unadjusted analyses, 257 
INR variability >0.75 was associated with higher risk of bleedings and death (P=0.0001 and 258 
P=0.0012, respectively) when compared with INR variability <0.75, while no significant difference 259 
was found with respect to risk of thromboembolism (P=0.15). In adjusted analyses, no significant 260 
difference between the two groups (INR variability >0.75 vs. <0.75) was found concerning the risk 261 
of thromboembolism (HR 0.63, 95% CI 0.37-1.07, P=0.087), bleedings (HR 0.72, 95% CI 0.44-262 
1.18, P=0.20), and mortality (HR 0.68, 95% CI 0.43-1.07, P=0.096) (Supplementary Table 5). 263 
     Additionally, a multivariable Cox regression aalysis with TTR as a time-dependent covariate 264 
was performed. The median amount of INR measurements per patient was 44 (IQR 19-90). No 265 
differences were found in terms of risk of thromboembolism (HR 0.87, 95% CI 0.30-2.52, P=0.80), 266 
bleeding (HR 1.23, 95% CI 0.51-2.97, P=0.65), or all-c use mortality (HR 1.57, 95% CI 0.64-3.89, 267 
P=0.33) between patients with TTR <70% and patients with TTR >70%.  268 
     Further, propensity score stratification analyses were performed yielding similar findings as the 269 
main results (Hazard ratio (HR) 0.51, 95% CI 0.27-0.95 and HR 0.59, 95% CI 0.33-1.06 for 270 
thromboembolism and bleeding, respectively). 271 
 272 
DISCUSSION 273 
In this study, we examined the association between th  quality of VKA treatment, as measured by 274 
TTR, and the risk of adverse outcomes in patients udergoing MHV replacement. Our study yielded 275 
three principal findings. First, baseline characteris ics were found similar between the two groups 276 
(TTR <70% vs. TTR >70%) with the exception that MMV patients more often had TTR <70%. 277 














was associated with an increased risk of thromboemblism but not bleeding and all-cause mortality, 279 
compared with TTR >70% in patients with MHV. 280 
 281 
Few studies have examined the association between baseline characteristics and quality of VKA 282 
treatment, though their findings have not been consistent. A Korean study showed no significant 283 
associations between variables and quality of VKA treatment in an adjusted model.6 Also, Wypasek 284 
et al. found in a multiple regression analysis thatMAV patients with TTR >60% did not differ from 285 
patients with TTR <60% with respect to demographic or cardiovascular risk factors, yet, coronary 286 
artery disease and previous stroke were associated wi h higher TTR, while CYP2C9*2 allele variant 287 
was associated with lower TTR.14 In studies on AF patients, variables associated with TTR have 288 
been summarized in the SAMe-TT2R2 score (female sex, age <60 years, medical history [more 289 
than two comorbidities], treatment [interacting drugs, eg. Amiodarone], tobacco use [doubled], race 290 
[doubled]); a higher score was associated with an increased risk of labile INR (reflected as low 291 
TTR) and outcomes.20,21 Hence, the current research gives an ambiguous picture of the association 292 
between baseline characteristics and the quality of TTR; thus, our study emphasizes the fact that it 293 
is difficult to predict which patients are susceptible of a low quality of VKA treatment. 294 
 295 
MMV have been shown to be more thrombogenic than MAV.22 The relative risk of prosthetic valve 296 
thrombosis have shown to be twice as high for MMV compared with MAV23, and also, the risk of 297 
mortality has been shown to be highest for patients with a MMV prosthesis.10 Overall, studies have 298 
shown that the risk of outcomes is higher in MMV patients compared with MAV patients.11,22,24 We 299 
found that MMV patients had lower quality of VKA treatment compared with MAV patients, and 300 
since lower TTR is associated with higher risk of outc mes, MMV patients are, prima facie, at 301 















Several studies have shown an association between increased risk of bleeding with increasing INR 304 
and increased risk of thromboembolic events with decreasing INR.3,13 Also, studies have shown that 305 
lack of anticoagulation treatment results in a thromb embolic rate of up to 12% per year for MAV 306 
patients and 22% per year for MMV patients, and that VKA treatment reduces these risks to 1-4 % 307 
per year.25  308 
     In our study, patients with TTR <70% had a signif cant higher risk of thromboembolism 309 
compared with patients with TTR >70%, and trends towards differences were observed regarding 310 
the risk of bleeding and all-cause mortality among groups. In the sensitivity analysis on INR 311 
variability, trends towards differences concerning the risk thromboembolism, bleeding, and all-312 
cause mortality were found, although no differences in outcomes were found in the time-dependent 313 
analysis among groups. The quality of VKA treatment is usually defined over a longer period of 314 
time as in our six months follow-up, but since the INR value can change rapidly, the time-315 
dependent analysis could give a more precise picture of the risk of outcomes at any given time. 316 
However, the amount of INR measurements showed great vari nce in our study population and as a 317 
result of the limited amount of INR measurements in ome patients, the time-dependent analysis has 318 
limited power because of its time specific nature.  319 
     Previous studies have focused on Cox regression analyses on TTR or INR variability, and the 320 
risk of outcomes in MHV patients has been associated with lower quality of TTR. Grzymala-321 
Lubanski et al. found that the risk of thromboembolic events, bleeding, and death was significantly 322 
higher at lower TTR levels in MHV patients10,11, while other studies found that high INR variability 323 
was associated with significant higher risk of thromboembolic events, bleeding, and mortality in 324 
MHV patients.19,26 The majority of these studies included rather small study populations. More 325 
work has been done regarding the quality of VKA treatment and the risk of outcomes in AF 326 
patients. Björck et al found that the risk of bleeding, thromboembolism, and mortality was higher at 327 














below mean5. Likewise, Gallagher et al. found that AF patients with TTR >70% had lower risk of 329 
stroke and mortality when compared with patients with TTR <70%.13 The studies on AF patients 330 
included large study populations compared with the studies on MHV patients, hence, our study is 331 
important because of a relatively large and representative study population of MHV patients. Thus, 332 
our study has the advantage of a more complete analysis that supports the current evidence on the 333 
association between low TTR (<70%) and high INR variability (>0.75) and a higher risk of adverse 334 
outcomes.  335 
 336 
Strengths and limitations 337 
The main strength of our study is the combination of complete administrative registries including 338 
data on hospital admissions, deaths, and filled prescriptions in Denmark in combination with data 339 
on INR values. This retrospective study was carried out on every patient with accessible data; 340 
however, the main limitation was the number of patients with accessible blood samples. In addition, 341 
patients can have their INR values analysed at general practitioners or by self-monitoring at home 342 
without reporting the result; thus the laboratory databases might not be fully representative, 343 
although we tried to overcome this challenge with the restriction of 60 days between measurements. 344 
Due to exclusion criteria, the study population is smaller than the total population undergoing 345 
mechanical heart valve replacement.  Further, TTR was calculated in a 6-month period, and so it 346 
cannot be excluded that TTR could change later on. Moreover, additional events may have occurred 347 
in the first six months post-discharge but these evnts are not included due to the nature of this 348 
study. We tried to overcome this challenge in the time-dependent analysis, however, due to a great 349 
variance of the amount of INR measurements per patient his analysis has limited power. Thus, 350 
more INR measurements will be needed in order to streng hen this sensitivity analysis. 351 
Additionally, patients may require anticoagulation interruption during surgical procedures etc. 352 














In the propensity score stratification analyses, similar results were found compared with the main 354 
analysis; the difference in risk of bleeding was non-significant between groups, however, a 355 
tendency towards a difference was found. The Cox analyses were adjusted for relevant 356 
demographics, comorbidities, and use of medication, yet the influence of potential confounders and 357 
thereby residual confounding cannot be omitted. 358 
 359 
Conclusions 360 
Our study supports the existing knowledge that low quality of VKA treatment, defined as TTR 361 
<70%, is associated with a higher risk of thromboembolic events compared with high quality of 362 
VKA treatment (TTR >70%), and also that MMV was associated with lower TTR compared with 363 
MAV. Therefore, it is essential to emphasize the awareness of the monitoring of anticoagulant 364 
therapy in every patient on OAC VKA treatment. For graphical overview of methods, results, and 365 
































Central picture Cumulative incidence of thromboembolism in patients with mechanical heart 372 
valves according to quality of VKA treatment (TTR >70% vs. TTR<70 %). TTR, Time in 373 
Therapeutic Range.  374 
 375 
Figure 1 Selection of the study population. INR: International Normalized Ratio 376 
 377 
Figure 2 Baseline characteristics associated with TTR <70% and TTR >70%.  378 
TTR: Time in therapeutic range. CI: Confidence intervals. COPD: Chronic obstructive lung disease.   379 
 380 
Figure 3 Cumulative incidence of thromboembolism in patients with mechanical heart valves 381 
according to quality of VKA treatment (TTR >70% vs. TTR <70%). TTR: Time in therapeutic 382 
range. VKA: vitamin K antagonists. 383 
 384 
Figure 4 Cumulative incidence of bleeding in patients with mechanical heart valves according to 385 
quality to quality of VKA treatment (TTR >70% vs. TTR <70%). TTR: Time in therapeutic range. 386 
VKA: vitamin K antagonists. 387 
 388 
Figure 5 Cumulative incidence of mortality in patients with mechanical heart valves according to 389 
quality of VKA treatment (TTR >70% vs. TTR <70%). TTR: Time in therapeutic range. VKA: 390 















Graphical abstract Association between quality of VKA treatment (TTR >70% vs. TTR <70%) 393 
and risk of outcomes in patients with mechanical heart valves and implications of the findings. 394 
VKA: vitamin K antagonists. TTR: Time in therapeutic range.  395 
 396 
Video The importance of monitoring the VKA therapy in patien s with mechanical heart valves. 397 
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Table 1 Baseline characteristics divided by TTR at time of discharge 480 
Variable TTR* <70 TTR >70 Standardized 
mean differences 
Number (%) 466 (70.7 %) 193 (29.3 %)  
Median age (IQR) 58.0 (50-64) 58.0 (49-64) -0.04 
Male sex (%) 319 (68.5 %) 149 (77.2 %) 0.20 
Comorbidities  
Ischemic heart disease 139 (29.7 %) 48 (25.0 %) -0.09 
Acute myocardial infarction 33 (7.1 %) 7 (3.7 %) -0.15 
Chronic heart failure 145 (31.1 %) 46 (24.0 %) -0.15 
Atrial fibrillation 140 (30.0 %) 52 (27.1 %) -0.05 
Stroke 56 (12.0 %) 14 (7.8 %) -0.14 
Transient ischemic attack 36 (7.7 %) 14 (7.29 %) 0.01 
Arterial embolism 4 (0.9 %) 3 (1.6 %) 0.06 
Pulmonic embolism 11 (2.4 %) 2 (1.0 %) -0.10 
Deep vein thrombosis 10 (2.1 %) 1 (0.5 %) -0.14 
Diabetes mellitus 19 (4.1 %) 14 (7.3 %) 0.05 
Peripheral vascular disease 20 (4.3%) 5 (2.6%) -0.09 
Coagulopathy 25 (5.4 %) 10 (5.2 %) -0.01 
Prior bleeding 110 (23.6 %) 46 (24.0 %) 0.02 
Chronic obstructive lung disease 40 (8.6 %) 18 (9.4%) 0.05 
Malignancy 73 (15.6 %) 32 (16.7 %) 0.02 
Abnormal liver function 17 (3.6 %) 6 (3.13 %) -0.03 
Chronic renal failure 29 (6.2 %) 11 (5.7 %) -0.02 
Aortic regurgitation 152 (32.6 %) 59 (30.7 %) -0.03 














Mitral regurgitation 107 (22.9 %) 22 (11.4 %) -0.31 
Mitral stenosis 34 (7.3 %) 12 (6.3 %) -0.31 
Endocarditis  95 (20.3 %) 32 (16.7 %) -0.10 
Alcohol abuse 32 (6.9 %) 14 (7.3 %) 0.02 
Hypertension 172 (36.9 %) 77 (39.9 %) 0.06 
Concomitant therapy  
Statins  95 (20.4 %) 48 (24.9 %) 0.11 
Beta-blockers 113 (24.3 %) 57 (29.5 %) 0.12 
Calcium channel blockers 78 (16.7 %) 40 (20.7 %) 0.10 
Renin-angiotensin system inhibitors 130 (27.9 %) 56 (29.0 %) 0.02 
Amiadarone 21 (4.5 %) 8 (4.15 %) -0.02 
Digoxin 53 (11.4 %) 22 (11.4 %) 0.00 
Acetylsalicylic acid 121 (26.0 %) 48 (25.0 %) -0.03 
ADPi† 4 (0.9 %) 2 (1.0 %) 0.02 
Dipyridamol 9 (1.9 %) 5 (2.6 %) 0.044 
Vitamin K antagonists  105 (22.5 %) 52 (26.9 %) 0.10 
Thiazid 71 (15.2 %) 35 (18.1 %) 0.08 
NSAID‡ 99 (21.2 %) 41 (21.4 %) 0.04 
*TTR: time in therapeutic range. †ADPi: adenosin diphosphate receptor inhibitors. ‡NSAID: non-
















Table 2 Time in therapeutic range (TTR) according to valve type 483 
 Combined MAV† MMV  
TTR* <70% 467 (70.9 %) 351 (66.6 %) 115 (87.1 %) 
TTR ≥70% 192 (29.1 %) 176 (33.4 %) 17 (12.9 %) 
Median TTR, (IQR) 54.9 (39.0-73.1) 58.9 (44.5-75.0) 37.0 (23.8-54.0) 
Mean TTR, (SD) 55.5 (24.0) 59.1 (22.9) 41.1 (22.9) 
 
*TTR: time in therapeutic range. Combined includes all patients with a mechanical aortic or mitral 
































 Events (n)  Hazard ratio (95% CI) P value 
TTR ≥70% TTR <70% 
Thromboembolism 13 66 0.44 (0.22-0.85) 0.02 
First year after index 3 10 
Remaining 9 years 
after index 
10 56 
Bleeding 25 69 0.63 (0.36-1.08) 0.05 
First year after index 5 10 
Remaining 9 years 
after index 
20 59 
All-cause mortality 21 74 0.84 (0.50-1.42) 0.52 
First year after index 2 5 




High (>70%) vs. low (<70%) TTR is considered high vs. low TTR quality, receptively.  
TTR >70% is set as reference for the analysis. 
HR is adjusted for sex, age, valve type, comorbidities (ischemic heart disease, chronic heart 
failure, atrial fibrillation, prior stroke, transient ischemic attack, peripheral vascular disease, 
coagulopathy, bleeding, chronic obstructive lung disease, malignancy, chronic renal failure, 
abnormal liver function, alcohol abuse, endocarditis, hypertension, and diabetes mellitus), and 
concomitant pharmacotherapy (statins, beta-blockers, calcium channel blockers, RAS inhibitors, 
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Supplementary Table 1 Comorbidities, pharmacotherapy, and outcomes 
Comorbidity 
 ICD-codes (ICD-8 and ICD-10) 
Ischemic heart disease ICD8: 410, 411, 412, 413, 414 
ICD10: I20, I21, I22, I23, I24, I25,  
AMI* ICD8: 410 
ICD10: I21, I22 
Chronic heart failure ICD8: 425, 428 
ICD10: I42, I50, I110, I130, I132, J819 
Atrial fibrillation ICD8: 42794, 42793 
ICD10: I48 
Stroke ICD8: 430, 431, 432, 433, 434, 436 
ICD10: I63, I64 
TIA† ICD8: 435 
ICD10: G45 
Arterial embolism ICD8: 444 
ICD10: I74 
Pulmonic embolism ICD8: 450 
ICD10: I26 
Deep vein thrombosis ICD8: 45100, 45108, 45109, 45190, 45199, 45300, 45302, 45303, 
45304, 45809 
ICD10: I801, I802, I803, I808, I809, I821, I822, I823, I828, I829 




















Coagulopathy ICD8: 286 
ICD10: D66. D67. D68, D69 
Bleeding ICD8-10: I60, I61, I62, N02, R31, R04, D62, H052A, G951A, 
S368D, K298A, K228F, I864A, K638B, K638C, K838F, K868G, 
I312, H313, H356, H431, H450, S064, S065, S066, J942, D500, 
K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, 
K274, K276, K280, K282, K286, K290, K625, K661, K920, K921, 
K922, I850  
Alcohol abuse ICD8: 57109, 57110, 57710 
ICD10: F10, K70, E52, T51, K860, E244, G312, I426, O354, Z714, 




ICD8: 490, 491, 492 
ICD10: J42, J43, J44 




ICD8: 571, 572, 573, 155, 070 
ICD10: B15-B19, K70-K77, C22, I982, Z944, D684C, Q618A 
Chronic renal failure ICD8: 403, 404, 581, 582, 583, 584, 25002, 50039, 59009, 59320, 
75310, 75311, 75319 
ICD10: N02, N03, N04, N05, N06, N07, N08, N11, N12, N14, 















Q612, Q613, Q615, Q619, E102, E112, E132, E142, I120, M300, 
M313, M319, T858, T859, Z992 
Aortic insufficiency ICD10: I351, I352 
Aortic stenosis ICD8: 395, 396 
ICD10: I350, Q253, I352 
Mitral insufficiency ICD8: 394, 396 
ICD10: I340, I051, I052, I348A 
Mitral stenosis ICD10: I050, I052, I342 
Endocarditis ICD8: 42100-42199, 42499 
ICD10: I33, I38, I398 
Pharmacotherapy 
 ATC code 
Statins  C10AA 
Beta-blockers C07, C09BX 
Calcium channel 
blockers 









Acetylsalicylic acid B01AC06 
















Vitamin K antagonists  B01AA03, B01AA04 
Antiadrenergic drugs C02A, C02B, C02C 
Thiazid C03A, C07B, C07D 
Loop diuretics C03C, C03EB01, C03EB02 
Spironolacton C03DA01 
Diuretics combined C07C, C08G, C03B, C09Ba, C09DA 
NSAID§ M01A 
Hypertension 2 or more of BB, CBB, RASi, antiadrenergics, thiazid, loop 





AMI, ischemic stroke, 
systemic embolism and 
thrombosis, TCI||) 
ICD8: 410 
ICD10: T828, I21, I22, I63, I64, G458, G459, I74 
Bleeding I60, I61, I62, N02, R31, R04, D62, H052A, G951A, S368D, 
K298A, K228F, I864A, K638B, K638C, K838F, K868G, I312, 
H313, H356, H431, H450, S064, S065, S066, J942, D500, K250, 
K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, 

















*AMI: acute myocardial infarction. † TIA: Transient ischemic attack. ‡ADPi: adenosin diphosphate 
receptor inhibitors. §NSAID: non-steroidal anti-inflammatory drugs. ||TCI: Transient Ischemic 
infarction  
 
Supplementary Table 2 Factors associated with thromboembolic events 
 Hazard ratio 
(95% Confidence interval) 
P value 
 
Age 0.99 (0.64-2.40) 0.55 
Sex (men) 1.23 (0.70-2.15) 0.21 
TTR >70% 0.44 (0.22-0.85) 0.01 
Mechanical aortic valve 1.24 (0.64-2.40) 0.53 
Ischemic heart disease 2.92 (1.70-5.00) 0.0001 
Heart failure 0.78 (0.44-1.38) 0.39 
Atrial fibrillation 0.46 (0.24-0.86) 0.01 
Stroke 12.26 (7.10-21.17) <0.0001 
Hypertension 2.28 (1.01-5.13) 0.05 
Diabetes mellitus 2.12 (0.66-6.80) 0.21 
Peripheral vascular disease 1.52 (0.65-3.55) 0.34 
Bleeding 1.05 (0.60-1.81) 0.88 
Alcohol abuse 1.41 (0.45-4.39) 0.55 
Chronic obstructive lung disease 1.02 (0.46-2.24) 0.97 
Malignancy 0.74 (0.37-1.51) 0.41 
Abnormal liver function 1.82 (0.58-5.76) 0.31 


















Supplementary Table 3 Factors associated with bleeding 
 Hazard ratio 
(95% Confidence interval) 
P value 
 
Age 1.01 (0.99-1.04) 0.40 
Sex (men) 1.49 (0.83-2.66) 0.18 
TTR >70% 0.63 (0.36-1.08) 0.09 
Mechanical aortic valve 0.71 (0.41-1.24) 0.23 
Ischemic heart disease 1.01 (0.60-1.70) 0.98 
Heart failure 0.99 (0.59-1.67) 0.97 
Atrial fibrillation 0.94 (0.57-1.57) 0.82 
Stroke 1.61 (0.81-3.22) 0.18 
Hypertension 2.61 (1.34-5.11) 0.005 
Diabetes mellitus 0.77 (0.26-2.27) 0.63 
Peripheral vascular disease 0.72 (0.30-1.70) 0.45 
Bleeding 15.93 (8.99-28.24) <0.0001 
Alcohol abuse 1.85 (0.95-3.61) 0.073 
Chronic obstructive lung disease 0.82 (0.39-1.71) 0.59 
Malignancy 1.58 (0.95-2.63) 0.08 
Abnormal liver function 2.62 (1.16-5.95) 0.02 
















Supplementary Table 4 INR variability according to valve type 
 Combined MAV* MMV† 
INR variability <0.75 446 (67.7 %) 291 (55.2 %) 39 (29.6 %) 
INR variability >0.75 213 (32.3 %)  236 (44.8 %) 93 (70.1 %) 
INR variability median, (IQR) 0.75 (0.49-1.16) 0.70 (0.46-1.06) 1.01 (0.61-1.34) 
INR variability mean, (SD) 0.94 (0.81) 0.86 (0.62) 1.25 (1.28) 
 
Combined includes all patients with a mechanical aortic r mitral valve.  

















Supplementary Table 5 Multivariable analysis on risk of thromboembolism, bleeding and all-
cause mortality depending on quality of VKA treatment using mean INR variability of 0.75 as cut-
off 







Thromboembolism 13.4% 10.6% 0.63 (0.37-1.07) 0.087 
Bleeding 19.2% 9.4% 0.72 (0.44-1.18) 0.20 
All-cause mortality 18.2% 10.6% 0.68 (0.43-1.07) 0.096 
 
High (>0.75) vs. low (<0.75) INR variability is considered low vs. high TTR quality, receptively. 
INR variability <0.75 is set as reference for the analysis 
HR is adjusted for sex, age, valve type, comorbidities (ischemic heart disease, chronic heart failure, 
atrial fibrillation, prior stroke, transient ischemic attack, peripheral vascular disease, coagulopathy, 
bleeding, chronic obstructive lung disease, malignancy, chronic renal failure, abnormal liver function, 
alcohol abuse, endocarditis, hypertension, and diabetes mellitus), and concomitant pharmacotherapy 


















Supplementary Table 6 Time-dependent multivariable Cox regression 
 Hazard ratio (95% Confidence interval) P value 
Thromboembolism 0.87 (0.30-2.52) 0.80 
Bleeding 1.23 (0.51-2.97) 0.65 
















Supplementary Table 7 Patients with TTR >70% versus TTR <70% over time (1996-2012) 
Year Patients with TTR >70% (%) Patients with TTR <70% 
1996 22.2% 77.8% 
1997 44.4% 55.6% 
1998 20.0% 80.0% 
1999 27.8% 72.2% 
2000 30.0% 70.0% 
2001 23.8% 76.2% 
2002 30.6% 69.4% 
2003 17.0% 83.0% 
2004 32.8% 67.2% 
2005 26.5% 73.5% 
2006 24.6% 75.4% 
2007 30.0% 70.0% 
2008 31.1% 68.9% 
2009 29.4% 70.6% 
2010 34.8% 65.2% 
2011 48.0% 52.0% 
2012 30.4% 69.6% 
 
 
